Literature DB >> 7704911

Enhanced T cell maturation and altered lineage commitment in T cell receptor/CD4-transgenic mice.

S A Lieberman1, L M Spain, L Wang, L J Berg.   

Abstract

The two mature subsets of T lymphocytes, CD4+ and CD8+ cells arise from a common progenitor during development in the thymus. The differentiation of this progenitor cell into one of the two mature T cell subsets is determined by the specificity of the alpha beta TCR for MHC class I or class II molecules. Using a line of TCR-transgenic mice expressing an MHC class II-specific TCR, 2B4, we have examined the thymocyte subsets present in a selecting versus a nonselecting MHC background. Our results are consistent with the model that CD4 versus CD8 downregulation occurs stochastically. In an effort to confirm these findings, we examined T cell development in double-transgenic mice expressing high levels of a CD4-transgene plus the 2B4 TCR transgenes. Unlike the findings with MHC class I-specific TCR-transgenic models, peripheral T cells in these mice include a substantial fraction of MHC class II-specific (2B4+) T cells expressing CD8 plus the transgene-encoded CD4. In addition, analysis of both thymocytes and peripheral T cells in these double-transgenic mice indicate that CD4 overexpression also leads to a striking enhancement of T cell maturation in 2B4 TCR-transgenic mice. Together with the studies of others, these data support a stochastic model for CD4 versus CD8 lineage commitment of an MHC class II-specific TCR during T cell development in the thymus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704911     DOI: 10.1006/cimm.1995.1051

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  T cell responses in calcineurin A alpha-deficient mice.

Authors:  B W Zhang; G Zimmer; J Chen; D Ladd; E Li; F W Alt; G Wiederrecht; J Cryan; E A O'Neill; C E Seidman; A K Abbas; J G Seidman
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.